Advanced breast cancer (metastatic)


by subject classification

selective estrogen receptor modulator (SERM) - tamoxifen - toremifene

all type of patients - pdf

AKT Inhibitors

all type of patients - pdf

HR+ HER2- - pdf

Angiogenesis inhibitors - aflibercept - bevacizumab - cediranib - motesanib - sorafenib - vandetanib

all type of patients - pdf

first line therapy - pdf

second line therapy - pdf

Anthracyclines based regimen

all type of patients - pdf

Aromatase inhibitors - aminoglutethimide - anastrozole - exemestane - fadrozole - formestane - letrozole

all type of patients - pdf

Capecitabine containing-regimen - capecitabine

all type of patients - pdf

Combination chemotherapy with platinum salts

all type of patients - pdf

Cyclin inhibitors - palbociclib

all type of patients - pdf

HR+ HER2- - pdf

FGFR inhibitors

all type of patients - pdf

HR+ HER2- - pdf

Gemcitabine containg regimen

all type of patients - pdf

HER2 inhibitors - pertuzumab - trastuzumab - trastuzumab emtansine

HER2 positive patients - pdf

all type of patients - pdf

High dose chemotherapy

all type of patients - pdf

Histone deacetylase (HDAC) inhibitors - entinostat

all type of patients - pdf

HR+ HER2- - pdf

Immune checkpoint inhibition - atezolizumab - avelumab - durvalumab - ipilimumab - nivolumab - pembrolizumab

all type of patients - pdf

Ixabepilone based chemotherapy

no longer responding to currently available chemotherapies - pdf

LHRH agonist

all type of patients - pdf

Locoregional treatment of the primary tumor

all type of patients - pdf

Maintenance chemotherapy

all type of patients - pdf

Monoclonal antibody

all type of patients - pdf

MTOR inhibitor - everolimus - temsirolimus - temsirolimus

HR+ HER2- - pdf

first line therapy - pdf

patients recurring or progressing after prior endocrine therapy - pdf

patient trastuzumab-resistant, and previously treated by taxanes - pdf

all type of patients - pdf

Multi target TKI - axitinib - dovitinib - pazopanib - sorafenib - sunitinib

HR+ HER2- - pdf

all type of patients - pdf

Nontaxane microtubule dynamics inhibitor - eribulin

all type of patients - pdf

Phosphoinositide 3-kinase inhibitor

HR+ HER2- - pdf

all type of patients - pdf

Poly ADP-ribose polymerase (PARP) inhibitor - niraparib - olaparib - talazoparib - veliparib

all type of patients - pdf

BRCA-mutated - pdf

HER 2 negative - pdf

Selective estrogen receptor downregulators (SERDs) - fulvestrant

patients recurring or progressing after prior endocrine therapy - pdf

first line endocrine therapy - pdf

all type of patients - pdf

Taxanes - docetaxel - nab-paclitaxel - paclitaxel

all type of patients - pdf

Vinorelbine containing regimen - vinorelbine

all type of patients - pdf